246 related articles for article (PubMed ID: 19329207)
1. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
[TBL] [Abstract][Full Text] [Related]
2. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Aerts HJ; Bussink J; Oyen WJ; van Elmpt W; Folgering AM; Emans D; Velders M; Lambin P; De Ruysscher D
Lung Cancer; 2012 Jan; 75(1):73-6. PubMed ID: 21782272
[TBL] [Abstract][Full Text] [Related]
3. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
4. Prediction of residual metabolic activity after treatment in NSCLC patients.
Velazquez ER; Aerts HJ; Oberije C; De Ruysscher D; Lambin P
Acta Oncol; 2010 Oct; 49(7):1033-9. PubMed ID: 20831492
[TBL] [Abstract][Full Text] [Related]
5. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
Petit SF; Aerts HJ; van Loon JG; Offermann C; Houben R; Winkens B; Ollers MC; Lambin P; De Ruysscher D; Dekker AL
Radiother Oncol; 2009 Jun; 91(3):393-8. PubMed ID: 19328570
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
9. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
[TBL] [Abstract][Full Text] [Related]
10. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
11. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
12. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study.
Aerts HJ; Bosmans G; van Baardwijk AA; Dekker AL; Oellers MC; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1402-7. PubMed ID: 18234432
[TBL] [Abstract][Full Text] [Related]
13. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
[TBL] [Abstract][Full Text] [Related]
14. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
15. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
16. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.
De Ruysscher D; Houben A; Aerts HJ; Dehing C; Wanders R; Ollers M; Dingemans AM; Hochstenbag M; Boersma L; Borger J; Dekker A; Lambin P
Radiother Oncol; 2009 Jun; 91(3):415-20. PubMed ID: 19195730
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.
Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A
Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer.
Carvalho S; Leijenaar RT; Velazquez ER; Oberije C; Parmar C; van Elmpt W; Reymen B; Troost EG; Oellers M; Dekker A; Gillies R; Aerts HJ; Lambin P
Acta Oncol; 2013 Oct; 52(7):1398-404. PubMed ID: 24047338
[TBL] [Abstract][Full Text] [Related]
20. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
Abramyuk A; Tokalov S; Zöphel K; Koch A; Szluha Lazanyi K; Gillham C; Herrmann T; Abolmaali N
Radiother Oncol; 2009 Jun; 91(3):399-404. PubMed ID: 19168248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
